These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8771599)

  • 21. [Evaluation of the efficacy and tolerability of fluoxetine in major depression, Multicenter clinical study].
    Cabras PL; Enriques E; Casini A; Paoletti C; Zagnoni P
    Minerva Psichiatr; 1991; 32(2):93-101. PubMed ID: 1870418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial.
    Noguera R; Altuna R; Alvarez E; Ayuso JL; Casais L; Udina C
    J Affect Disord; 1991 Jul; 22(3):119-24. PubMed ID: 1918655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.
    Onder E; Tural U
    J Affect Disord; 2003 Sep; 76(1-3):223-7. PubMed ID: 12943952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine.
    Harrer G; Schmidt U; Kuhn U; Biller A
    Arzneimittelforschung; 1999 Apr; 49(4):289-96. PubMed ID: 10337446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships among measures of treatment outcome in depressed patients.
    Mulder RT; Joyce PR; Frampton C
    J Affect Disord; 2003 Sep; 76(1-3):127-35. PubMed ID: 12943942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of response to desipramine in dysthymia.
    Friedman RA; Parides M; Baff R; Moran M; Kocsis JH
    J Clin Psychopharmacol; 1995 Aug; 15(4):280-3. PubMed ID: 7593711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What constitutes an adequate antidepressant trial for fluoxetine?
    Schweizer E; Rickels K; Amsterdam JD; Fox I; Puzzuoli G; Weise C
    J Clin Psychiatry; 1990 Jan; 51(1):8-11. PubMed ID: 2403998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Major agitated-anxious versus blunted-retarded depression: differential effects of fluoxetine].
    Dalery J; Bouhassira M; Kress JP; Lancrenon S; Tafani A; Hantouche EG
    Encephale; 1995; 21(3):217-25. PubMed ID: 7649072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoxetine in patients with major depressive disorder--a responder analysis.
    Klieser E; Lehmann E; Heinrich K
    Pharmacopsychiatry; 1995 Jan; 28(1):14-9. PubMed ID: 7746839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rating dysthymia: an assessment of the construct and content validity of the Cornell Dysthymia Rating Scale.
    Hellerstein DJ; Batchelder ST; Lee A; Borisovskaya M
    J Affect Disord; 2002 Sep; 71(1-3):85-96. PubMed ID: 12167504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
    Gillin JC; Rapaport M; Erman MK; Winokur A; Albala BJ
    J Clin Psychiatry; 1997 May; 58(5):185-92. PubMed ID: 9184611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications.
    Revicki DA; Wood M
    J Affect Disord; 1998 Feb; 48(1):25-36. PubMed ID: 9495599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.
    De Bellis MD; Geracioti TD; Altemus M; Kling MA
    Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):636-41. PubMed ID: 7687151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
    Perry PJ; Garvey MJ; Kelly MW; Cook BL; Dunner FJ; Winokur G
    J Clin Psychiatry; 1989 Aug; 50(8):290-4. PubMed ID: 2668259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
    Fava M; Rappe SM; Pava JA; Nierenberg AA; Alpert JE; Rosenbaum JF
    J Clin Psychiatry; 1995 Feb; 56(2):52-5. PubMed ID: 7852252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.
    Zisook S; Peterkin J; Goggin KJ; Sledge P; Atkinson JH; Grant I
    J Clin Psychiatry; 1998 May; 59(5):217-24. PubMed ID: 9632030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.
    Stewart JW; Quitkin FM; McGrath PJ; Amsterdam J; Fava M; Fawcett J; Reimherr F; Rosenbaum J; Beasley C; Roback P
    Arch Gen Psychiatry; 1998 Apr; 55(4):334-43. PubMed ID: 9554429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.
    Heiligenstein JH; Tollefson GD; Faries DE
    J Affect Disord; 1994 Mar; 30(3):163-73. PubMed ID: 8006243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.